

Aralast™ NP, Glassia™, Prolastin-C®, and Zemaira® (alpha₁-proteinase inhibitor [human])

When requesting Aralast NP, Glassia, Prolastin-C, and Zemaira (alpha₁-proteinase inhibitor [human]), the individual requiring treatment must be diagnosed with an FDA-approved indication or approved compendial use and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Aralast NP, Glassia, Prolastin-C and Zemaira are alpha₁-proteinase inhibitors indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital deficiency of alpha₁-antitrypsin (AAT) deficiency.

Approved Off-label Compendial Use

Panniculitis due to alpha₁-antitrypsin (AAT) deficiency

Coverage Guidelines

Emphysema due to AAT deficiency

The individual must meet **all** of the following criteria for authorization:

- Is 18 years of age or older;
- Has a baseline (pretreatment) AAT serum concentration less than 11 micromol/L (less than 80 mg/dL if measured by radial immunodiffusion or less than 57 mg/dL if measured by nephelometry);
- Is currently a nonsmoker.

Panniculitis due to AAT deficiency

The individual must be 18 years of age or older for authorization.

Approval duration: 12 months

Dosing Recommendation

The recommended dose is 60 mg/kg administered once weekly by intravenous infusion.

References

1. Aralast NP® intravenous infusion [prescribing information]. Lexington, MA: Shire; December 2018.
2. Zemaira® intravenous infusion [prescribing information]. Kankakee, IL: CSL Behring; April 2019.
3. Prolastin®-C intravenous infusion [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; June 2018.
4. Prolastin®-C Liquid intravenous infusion [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; August 2018.
5. Glassia® intravenous infusion [prescribing information]. Lexington, MA: Shire; June 2017.
6. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. *Eur Respir J*. 2017;50(5).
7. Brantly ML, Lascano JE, Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. *Chronic Obstr Pulm Dis*. 2018;6(1):100-114.
8. Stoller JK, Lacbawan FL, Aboussouan LS. Alpha-1 Antitrypsin Deficiency. 2006 Oct 27 [Updated 2020 May 21]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1519>. Accessed on November 16, 2022.
9. Miravittles M, Herr C, Ferrarotti I, et al. Laboratory testing of individuals with severe alpha1-antitrypsin deficiency in three European centres. *Eur Respir J*. 2010 May;35(5):960-968.
10. American Thoracic Society and the European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003;168:818-900.
11. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. *Can Respir J*. 2012;19:109-116.
12. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. *Chronic Obstr Pulm Dis*. 2016;3(3):668-682.
13. Sabbagh DK, Barmayehvar B, Nguyen T, Edgar RG, Turner AM. Managing panniculitis in alpha-1 antitrypsin deficiency: systematic review of evidence behind treatment. *World J Dermatol*. 2018;7(1):1-8.
14. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2022. Available at: <https://goldcopd.org/2022-gold-reports-2/>. Accessed on November 14, 2022.